ScholarLens Back to search
2012•Leukemia ResearchRequires access

Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

Ho‐Young Yhim, Na‐Ri Lee, Eun‐Kee Song, Chang‐Yeol Yim, So Yeon Jeon, Seung-Hwan Shin, Jeong‐A Kim, Hee Sun Kim, Eun‐Hae Cho, Jae‐Yong Kwak

Open publisher page 63 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 63 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Discontinuation, Imatinib mesylate, Medicine, Myeloid leukemia, Imatinib, Internal medicine, Oncology

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response — Research Paper | ScholarLens